The FDA granted Janssen’s TB drug Bedaquiline accelerated approval for treatment of MDR-TB. A link is provided to the FDA press release and Janssen’s full press release is included.
The WHO released the Global Tuberculosis Report 2012 today. The main highlights and additional coverage are included.
This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.
This week we highlight a study showing promising results that providing high dose vitamin D supplements along with antibiotics could improve treatment outcomes for TB patients. The abstract and additional news coverage are included, as well as, links to other TB R&D news.
We will have our 2012 Annual Meeting in Kuala, Lumpur on Wednesday, November 14 at the Impiana KLCC Hotel from 13:00 to 17:30. The meeting will be held in conjunction with the 43rd Union World Conference on Lung Health.
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.
TB REACH is currently accepting applications for Wave 3. The deadline for submitting proposals for Wave 3 is 17 September 2012.
The inaugural InTB contest winners are announced in three categories: Overall Winner, Advocacy Winner, and Fan Favorite. Thank you to all entrants. Keep submitting your innovations to grow the InTB library!
This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207).
This week we highlight an interview with Jeannine Uwimana, a public health specialist from the University of the Western Cape and TB/HIV Care Association in South Africa. She discusses her work in developing models for community-based programs to enhance TB and HIV collaborative activities.